1. Home
  2. BOLD vs DTST Comparison

BOLD vs DTST Comparison

Compare BOLD & DTST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • DTST
  • Stock Information
  • Founded
  • BOLD 2018
  • DTST 2001
  • Country
  • BOLD United States
  • DTST United States
  • Employees
  • BOLD N/A
  • DTST N/A
  • Industry
  • BOLD
  • DTST EDP Services
  • Sector
  • BOLD
  • DTST Technology
  • Exchange
  • BOLD Nasdaq
  • DTST Nasdaq
  • Market Cap
  • BOLD 24.4M
  • DTST 28.2M
  • IPO Year
  • BOLD 2024
  • DTST N/A
  • Fundamental
  • Price
  • BOLD $1.15
  • DTST $3.48
  • Analyst Decision
  • BOLD Buy
  • DTST
  • Analyst Count
  • BOLD 3
  • DTST 0
  • Target Price
  • BOLD $4.00
  • DTST N/A
  • AVG Volume (30 Days)
  • BOLD 277.1K
  • DTST 30.5K
  • Earning Date
  • BOLD 08-11-2025
  • DTST 08-13-2025
  • Dividend Yield
  • BOLD N/A
  • DTST N/A
  • EPS Growth
  • BOLD N/A
  • DTST N/A
  • EPS
  • BOLD N/A
  • DTST 0.02
  • Revenue
  • BOLD N/A
  • DTST $25,219,312.00
  • Revenue This Year
  • BOLD N/A
  • DTST $12.57
  • Revenue Next Year
  • BOLD N/A
  • DTST $9.29
  • P/E Ratio
  • BOLD N/A
  • DTST $147.31
  • Revenue Growth
  • BOLD N/A
  • DTST N/A
  • 52 Week Low
  • BOLD $1.00
  • DTST $2.93
  • 52 Week High
  • BOLD $4.72
  • DTST $6.53
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • DTST 49.14
  • Support Level
  • BOLD N/A
  • DTST $3.33
  • Resistance Level
  • BOLD N/A
  • DTST $3.56
  • Average True Range (ATR)
  • BOLD 0.00
  • DTST 0.13
  • MACD
  • BOLD 0.00
  • DTST 0.01
  • Stochastic Oscillator
  • BOLD 0.00
  • DTST 58.56

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About DTST Data Storage Corporation

Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.

Share on Social Networks: